Browse > Article
http://dx.doi.org/10.3904/kjm.2012.82.6.689

$^{18}F-FDG$ PET/CT in the Clinical Assessment of Patients with Multiple Myeloma: A Pilot Study  

Kim, Hyun-Jung (Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Park, Jung-Mi (Department of Internal Medicine and Radiology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Cha, Jang-Gyu (Department of Internal Medicine and Radiology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Yun, Jin-A (Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Kim, Se-Hyung (Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Kim, Chan-Kyu (Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Park, Seong-Kyu (Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Hong, Dae-Sik (Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.82, no.6, 2012 , pp. 689-695 More about this Journal
Abstract
Background/Aims: This study investigated the clinical utility of positron emission tomography/computed tomography (PET/CT) for evaluating bone lesions in patients with multiple myeloma before therapy. Methods: Whole-spine and pelvic magnetic resonance imaging (MRI) and whole-body PET/CT were conducted in patients newly diagnosed with multiple myeloma before therapy. We compared the PET/CT and MRI results for the entire spine and pelvis, and the discordance rates were cross-analyzed with the clinical factors. Results: Ten patients were enrolled (median age 57.5 years). The majority were at an advanced stage, and IgG type multiple myeloma occurred in seven patients. All patients underwent PET/CT and 36 sites were checked on MRI. Approximately 69% of the patients had diffuse patterns, 8.3% had focal lesions, 5.6% had mixed lesions, and 16.7% had a normal pattern on MRI. The concordance rate of PET/CT compared with MRI was 83.3% (30 sites). The false-positive rate was 13.9% and the false-negative rate was 2.8%. No factor predicted the discordance between the PET/CT and MRI results. Conclusions: A well-designed, large-scale study is warranted to confirm the accuracy of PET/CT for detecting bone lesions in these patients.
Keywords
Multiple myeloma; PET/CT; MRI;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32-75.   DOI   ScienceOn
2 Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol 2011;29:1907-1915.   DOI   ScienceOn
3 Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 2009;70:393-400.   DOI   ScienceOn
4 Hoh CK. Clinical use of FDG PET. Nucl Med Biol 2007;34: 737-742.   DOI   ScienceOn
5 Haznedar R, Akı SZ, Akdemir OU, et al. Value of 18Ffluorodeoxyglucose uptake in positron emission tomography/ computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 2011;38:1046-1053.   DOI   ScienceOn
6 Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol 2007;36:5-16.   DOI   ScienceOn
7 Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011;118:5989-5995.   DOI   ScienceOn
8 Libshitz HI, Malthouse SR, Cunningham D, MacVicar AD, Husband JE. Multiple myeloma: appearance at MR imaging. Radiology 1992;182:833-837.   DOI
9 Moulopoulos LA, Varma DG, Dimopoulos MA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992;185: 833-840.   DOI
10 Stabler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996; 167:1029-1036.   DOI   ScienceOn
11 Vande Berg BC, Lecouvet FE, Michaux L, Ferrant A, Maldague B, Malghem J. Magnetic resonance imaging of the bone marrow in hematological malignancies. Eur Radiol 1998;8:1335-1344.   DOI   ScienceOn
12 Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009;23:1545-1556.   DOI   ScienceOn
13 Wang K, Allen L, Fung E, Chan CC, Chan JC, Griffith JF. Bone scintigraphy in common tumors with osteolytic components. Clin Nucl Med 2005;30:655-671.   DOI   ScienceOn
14 Shortt CP, Carty F, Murray JG. The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma. Semin Musculoskelet Radiol 2010;14:37-46.   DOI   ScienceOn
15 D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007;137:49-63.   DOI
16 Lutje S, de Rooy JW, Croockewit S, Koedam E, Oyen WJ, Raymakers RA. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009;88: 1161-1168.   DOI   ScienceOn
17 Castellani M, Carletto M, Baldini L, et al. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. Clin Nucl Med 2010;35:1-5.   DOI   ScienceOn
18 Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361-366.   DOI   ScienceOn
19 Sager S, Ergül N, Ciftci H, Cetin G, Güner SI, Cermik TF. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skeletal Radiol 2011;40:843-847.   DOI   ScienceOn
20 Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008;49:1928-1935.   DOI   ScienceOn